Use of the Thyroid Hormone Analogue Eprotirome in Statin ... Karo Bio presented the first clinical phase II data demonstrating that profound blood lipid lowering may be achieved while avoiding cardiac and other side effects typically associated with non–selective thyromimetics.KARO BIO HAS PRESENTED POSITIVE KB2115 PHASE II DATA AT TWO ... Karo Bio has completed the first single ascending dose part of its phase 1 study for KB with a successful outcome. The study, conducted with overweight but healthy individuals with elevated blood lipids, shows that KB was well tolerated and no adverse events was observed.CLINICAL STUDIES FOR KB2115 INITIATED - Karo Healthcare Karo Bio has initiated Phase I clinical studies for KB which is a compound with promising properties for treatment of obesity and dyslipidemia. The primary goal with the study is to evaluate tolerability, safety and pharmacokinetics as well as effects on high blood lipids and other cardiovascular risk factors. KARO BIO INITIATES PHASE IIb CLINICAL STUDY WITH KB2115
Eprotirome (KB) (Karo Bio) is a thyroid hormone analogue containing two bromides that, as compared with triiodothyronine, has minimal uptake in nonhepatic tissues. CLINICAL STUDIES FOR KB2115 INITIATED - Karo Pharma - Cision News
The thyroid hormone mimetic compound KB lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. 1. Karo Bio AB, Novum Research Park, S 57 Huddinge, Sweden. A comment on this article appears in "Thyroid mimetic as an option for lowering low-density lipoprotein.".
From the Cover: The thyroid hormone mimetic compound KB2115 ...
We report here studies on a selective thyromimetic [KB; (3- [ [3,5-dibromo [4-hydroxy (1-methylethyl)-phenoxy]-phenyl]-amino]oxopropanoic acid)] in humans.
| Kb2115 karo biography |
KB2115 is a selective thyroid hormone receptor modulator that in previous phase I studies has shown satisfactory pharmacokinetic and bioavailability properties. |
| Kb2115 karo biography wikipedia |
KB2115 induces a profound and clinically relevant lowering of a number of risk factors for development of cardiovascular disease and was well tolerated in the. |
| Kb2115 karo biography pdf |
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio (STO:KARO) Eprotirome (new generic name for KB2115) is a new compound that lowers high blood. |
| Kb2115 karo biography pictures |
The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. |
This study will be conducted in dyslipidemia patients receiving concomitant statin treatment.
The thyroid hormone mimetic compound KB lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans.KARO BIO PRESENTS POSITIVE KB2115 PHASE IIa PROOF OF CONCEPT DATA AT TWO MAJOR SCIENTIFIC MEETINGS KB2115 induces a profound and clinically relevant.
“We are excited about the profile of KB which represents the first compound from Karo Bio’s research entering phase II studies”, says Per Olof Wallström, President of Karo Bio. “This is a landmark for the company, and confirms our strategy to drive projects further into clinical development before potential partnering negotiations.
PHASE 1A CLINICAL TRIAL WITH KB2115 SUCCESSFULLY COMPLETED
Karo Bio has through a number of animal studies showed that KB increases the body’s energy consumption and reduce body weight and markedly reduces blood lipids and blood glucose. KB works by stimulating the thyroid hormone receptor which is the protein in the body that mediates the effects of thyroid hormone. KARO BIO INITIATES THE FIRST PHASE II STUDY WITH KB2115
KARO BIO INITIATES PHASE IIb CLINICAL STUDY WITH KB Karo Bio has received approval for initiation of a phase IIb clinical study with KB This. Karo Bio has received approval for initiation of a phase IIb clinical study with KB This study will be conducted in dyslipidemia patients receiving concomitant statin treatment. KB were administered up to 2, g. In the second study, placebo or KB at 50, , and g was administered orally once daily for 2 weeks. No effects were observed at any dose on body weight or oxygen consumption. The pharmacokinetics of KB were linear (Fig. 1). The drug was rapidly absorbed with a half-life of 2 h, and no.